IMGN ImmunoGen, Inc.

+1  (17%)
Previous Close 3.58
Open 3.59
Price To book 0.00
Market Cap 366.91M
Shares 87,569,000
Volume 7,174,695
Short Ratio 5.09
Av. Daily Volume 1,898,550

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved Feb 22 2013 - under priority review
2nd-line HER2+ Metastatic Breast Cancer
Phase 1b/2 initial data due 2Q 2017.
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer
Phase 2 initiated 2016
IMGN529 and rituximab
Cancer - diffuse-large B-cell lymphoma (DLBCL)
Reported April 2016 that FORWARD I, initially a Phase 2 trial, will now be a Phase 3 trial with progression-free survival as the primary endpoint. Announced January 26, 2017 that first patient has been dosed.
Mirvetuximab soravtansine - FORWARD I
Cancer - ovarian cancer and relapsed endometrial cancer
Phase 3 trial did not meet endpoints.
Kadcyla KRISTINE trial
HER2-positive breast cancer - neo-adjuvant setting
Endpoint not met - October 2015
Kadcyla GATSBY trial
Cancer - metastatic HER2+ gastric cancer
Phase 3 data due in 2019.
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
Phase 3 data due in 2018.
Kadcyla (KATHERINE).
HER2-positive breast cancer - residual invasive disease
Phase 3 data released Dec 18 2014. Met non-inferiority endpoint but did NOT significantly improve PFS compared to Herceptin and chemotherapy
Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) - Kadcyla - MARIANNE trial
Cancer - 1st-line HER2+ Metastatic Breast Cancer

Latest News

  1. ImmunoGen, Inc. – Value Analysis (NASDAQ:IMGN) : April 21, 2017
  2. ImmunoGen Announces Conference Call to Discuss Its First Quarter 2017 Financial Results
  3. Why ImmunoGen, Inc. Jumped Higher Today
  4. ImmunoGen, Inc. breached its 50 day moving average in a Bullish Manner : IMGN-US : April 20, 2017
  5. Why ImmunoGen, Inc. Shot Up Today
  6. Today's Research Reports on Biotech Stocks to Watch: Array Biopharma and ImmunoGen
  7. Why ImmunoGen, Inc. Stock Jumped Higher Today
  8. China's Creat Makes 1.2 Bln Euro Bid for German Blood Plasma Firm
  9. ImmunoGen (IMGN) Up 47.2% Since Earnings Report: Can It Continue?
  10. TG Therapeutics and ImmunoGen are Models of Institutional Investor Attention
  11. ImmunoGen Presents Phase 1 Biopsy Expansion Cohort Data at the Society of Gynecologic Oncology Annual Meeting
  12. Here's Why ImmunoGen, Inc. Skyrocketed 45% in February
  13. 3 Charts That Show the Potential Risks and Rewards for Immunogen, Inc. Stock
  14. ImmunoGen Announces Presentations at AACR Annual Meeting
  15. Why ImmunoGen, Inc. Skyrocketed Higher Today
  16. Today's Research Reports on Stocks to Watch: Micron Technology and ImmunoGen
  17. ImmunoGen, Inc.: Waiting to Move FORWARD
  18. ImmunoGen 4Q Loss Misses Street Expectations
  19. ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y
  20. Edited Transcript of IMGN earnings conference call or presentation 17-Feb-17 1:00pm GMT